Follows adults with severe chronic lung disease in Brazil over time
Observes adults with severe COPD, a long-term lung disease, at Brazilian hospitals.
Plain-language title generated from the registry record
Registry title: Study That Will Evaluate the Brazilian Population With COPD.
Key facts
- Where
- Aparecida de Goiânia, Bahia, Belém, Brasília, Campo Grande, Florianópolis, Goiânia, Santo André, São Paulo, and Uberlândia, BrazilSee the 10 sites
Where in Brazil
- Aparecida de GoiâniaAparecida de Goiânia, BrazilTaking people
- BahiaBahia, BrazilTaking people
- BelémBelém, BrazilTaking people
- BrasíliaBrasília, BrazilTaking people
- Campo GrandeCampo Grande, BrazilTaking people
- FlorianópolisFlorianópolis, BrazilTaking people
- GoiâniaGoiânia, BrazilTaking people
- Santo AndréSanto André, BrazilTaking people
- São PauloSão Paulo, BrazilTaking people
- UberlândiaUberlândia, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06780046
- Record updated
- 16 October 2026
- Original description
Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.Read full original descriptionShow less
Prospective Multicentric Cohort Study of Severe and Very Severe COPD Patients in Brazil.
Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.
Inclusion: Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT >=10); or; GOLD E (>=2 moderate or 1 severe exacerbation - hospitalization); or; GOLD 3 and 4 (FEV1 <50%).
Exclusion: Advanced fibrosing interstitial lung disease (extent >=50%); and/or; High-risk pulmonary hypertension (on triple therapy); and/or; Active cancer - on systemic therapy.